Cold chain shipping
Some medicinal ingredients are susceptible to damage from heat, light and handling. Using "cold chain" delivery, specialised medical couriers have temperature regulated boxes and vehicles to ensure that the medicine is uncompromised. For that reason, cold chain shipping can be more expensive than regular shipping. For more details,
Four steps to access the medicines you need
How and where to access and buy Evkeeza: You can access Evkeeza from picifix.com if the drug has not been approved or is not available in your country.
You send a request for your medicine online
Submit a request for a specific medicine, or a general request, and your Patient Support Manager will contact you within 24 hours. They will be there to support and guide you in anyway possible to help you get the medicine you need.
We verify your prescription and medical details
Since we help patients access medicines not available in their home country, our first step is to check that the medicine you need is not currently available in your home country. Next we will also verify that you have a prescription from a doctor in your home country for the medicine you need.
We source your medicine
Once we have verified your prescription and medical details, our expert sourcing team will work with our global network of suppliers to find you the best price. Once we have found you the lowest possible cost for your medicine, we will present you with a final offer for your approval.
We deliver your medicine
After you have accepted our offer, our experienced logistics team will arrange all the shipping and transportation of your medicine. We will work hard to keep you informed at every step along the way and get your medicine to you quickly and safely. To date we have successfully delivered packages to over 75 countries around the world.
What is Evkeeza (evinacumab) for?
Evkeeza (evinacumab) is an ANGPTL3 (angiopoietin-like 3) inhibitor used together with other low-density lipoprotein (LDL)-lowering medicines in people aged 12 years and older with a type of high cholesterol called Homozygous Familial Hypercholesterolemia (HoFH).
It is not known if Evkeeza (evinacumab) is safe and effective in people with other causes of high cholesterol.
This medicine is available in vial form for intravenous infusion, containing either 345 mg/2.3 mL (150 mg/mL) or 1,200 mg/8 mL (150 mg/mL) evinacumab.
How does Evkeeza (evinacumab) work?
HoFH is a rare, life-threatening disease, in which people have a mutation in their low-density lipoprotein (LDL) receptor. As a result, they have extremely high blood levels of LDL cholesterol (LDL-C), known as “bad cholesterol”. People with HoFH have increased risk of developing cardiovascular disease, including heart attack and heart disease, at a young age.[2,3]
Evinacumab is a monoclonal antibody, a type of protein, that can bind to the angiopoietin-like protein 3 (ANGPTL3). ANGPTL3 inhibits the function of enzymes in the body that break down fats. By inhibiting ANGPTL3, evinacumab helps speed up the breakdown of fats that lead to high cholesterol levels.[2,3]
Where has Evkeeza (evinacumab) been approved?
Evkeeza (evinacumab) was approved for the treatment of people with HoFH by:
The Food and Drug Administration (FDA), USA on February 11, 2021.
The European Medicines Agency (EMA) on April 21, 2021.
Evkeeza (evinacumab) was approved under Priority Review and was previously granted Orphan Drug designation, which provides incentives to assist and encourage drug development for rare diseases and Breakthrough Therapy designation.
Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team.
How is Evkeeza (evinacumab) taken?
The standard dosage is:
15 mg/kg body weight administered by intravenous (IV) infusion (drip) once monthly (every 4 weeks)
The diluted solution is given via IV infusion over 60 minutes through an IV line.
This medicine should not be mixed with other medications or given together with other medications concomitantly via the same infusion line.
LDL-C should be assessed when clinically possible. The LDL-lowering effect of Evkeeza (evinacumab) may be measured as early as 2 weeks after start of treatment.
Complete information about Evkeeza (evinacumab) infusion preparation, dosage and administration can be found in the official prescribing information listed in our references section.
Note: Please consult with your treating doctor for personalised dosing.
Are there any known adverse reactions or side effects of Evkeeza (evinacumab)?
Common adverse reactions
The most common side effects ( ≥5% of patients) listed in the prescribing information include:
Symptoms of the common cold (nasopharyngitis)
Pain in legs or arms
Serious adverse reactions
The serious adverse reactions listed in the prescribing information include:
Allergic reactions (hypersensitivity), including a severe reaction known as anaphylaxis
Use in a specific population
Evkeeza (evinacumab) can be fatal for a fetus, it is advised to avoid pregnancies. It is not known if Evkeeza (evinacumab) passes into your breast milk. Discuss with your treating doctor if you will receive this medicine or breastfeed.
It is not known if Evkeeza (evinacumab) is safe and effective in children with HoFH under 12 years of age.
For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information.[